These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9162355)

  • 1. [Ureteral jet in patients with benign prostatic hypertrophy: prognostic evaluation during single and combined therapy].
    Sperandeo M; Sperandeo G; Carella M; Bianco G; Cera A; Scarale MG; Viola M
    Arch Ital Urol Androl; 1996 Dec; 68(5 Suppl):175-8. PubMed ID: 9162355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ureteral jet during medical treatment of benign prostatic hypertrophy].
    Sperandeo M; Varriale A; Sperandeo G; Caturelli E; Dragone M
    Arch Ital Urol Androl; 1994 Sep; 66(4 Suppl):45-8. PubMed ID: 7534167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terazosin vs finasteride for BPH.
    Zacks M
    J Fam Pract; 1996 Dec; 43(6):533. PubMed ID: 8969692
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of benign prostatic hyperplasia.
    Walsh PC
    N Engl J Med; 1996 Aug; 335(8):586-7. PubMed ID: 8678937
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
    Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
    J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the best medical treatment for benign prostate hyperplasia?
    Evans MF; Frank J
    Can Fam Physician; 1997 Jun; 43():1073-4. PubMed ID: 9189295
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacologic treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2003 Sep; 144(37):1809-14. PubMed ID: 14596018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study provides head-to-head comparison of terazosin, finasteride.
    Am J Health Syst Pharm; 1996 Oct; 53(20):2380, 2382. PubMed ID: 8899123
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gonzalez CM; McVary KT
    Curr Urol Rep; 2003 Aug; 4(4):276-81. PubMed ID: 12882718
    [No Abstract]   [Full Text] [Related]  

  • 17. FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
    Rich KT; Safranek S
    Am Fam Physician; 2008 Mar; 77(5):665-6. PubMed ID: 18350766
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination drug therapy for benign prostatic hyperplasia.
    Kreder KJ
    JAMA; 1995 Jul; 274(4):359. PubMed ID: 7541871
    [No Abstract]   [Full Text] [Related]  

  • 19. Terazosin, finasteride, or both in benign prostatic hyperplasia.
    Kuchel GA; DuBeau CE; Resnick NM
    N Engl J Med; 1997 Jan; 336(4):293-4; author reply 294. PubMed ID: 9005317
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.